JP2011507977A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011507977A5 JP2011507977A5 JP2010541519A JP2010541519A JP2011507977A5 JP 2011507977 A5 JP2011507977 A5 JP 2011507977A5 JP 2010541519 A JP2010541519 A JP 2010541519A JP 2010541519 A JP2010541519 A JP 2010541519A JP 2011507977 A5 JP2011507977 A5 JP 2011507977A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- powder
- ray diffraction
- trifluoroethoxy
- sulfinyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000634 powder X-ray diffraction Methods 0.000 claims 12
- 239000013078 crystal Substances 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 6
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 claims 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 208000008469 Peptic Ulcer Diseases 0.000 claims 1
- 238000002425 crystallisation Methods 0.000 claims 1
- 230000008025 crystallization Effects 0.000 claims 1
- 208000011906 peptic ulcer disease Diseases 0.000 claims 1
- XTUSEBKMEQERQV-UHFFFAOYSA-N propan-2-ol;hydrate Chemical compound O.CC(C)O XTUSEBKMEQERQV-UHFFFAOYSA-N 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1802107P | 2007-12-31 | 2007-12-31 | |
| PCT/US2008/088534 WO2009088857A1 (en) | 2007-12-31 | 2008-12-30 | Crystalline solvated forms of (r) -2- [ [ [3-methyl-4- (2, 2, 2-trifluoroethoxy) -2-pyridinyl] methyl] sulfinyl] -1h-benz imidazole |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011507977A JP2011507977A (ja) | 2011-03-10 |
| JP2011507977A5 true JP2011507977A5 (enExample) | 2012-02-09 |
Family
ID=40364382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010541519A Abandoned JP2011507977A (ja) | 2007-12-31 | 2008-12-30 | （ｒ）−２−［［［３−メチル−４−（２，２，２−トリフルオロエトキシ）−２−ピリジニル］メチル］スルフィニル］−１ｈ−ベンズイミダゾールの溶媒和物結晶形 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20100286400A1 (enExample) |
| EP (3) | EP2292612A3 (enExample) |
| JP (1) | JP2011507977A (enExample) |
| CA (2) | CA2738458A1 (enExample) |
| WO (1) | WO2009088857A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ588379A (en) | 2008-03-10 | 2012-07-27 | Takeda Pharmaceutical | Crystal of benzimidazole compound |
| WO2010039885A2 (en) * | 2008-09-30 | 2010-04-08 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of dexlansoprazole |
| IT1391776B1 (it) | 2008-11-18 | 2012-01-27 | Dipharma Francis Srl | Procedimento per la preparazione di dexlansoprazolo |
| WO2010095144A2 (en) * | 2009-02-04 | 2010-08-26 | Msn Laboratories Limited | Process for the preparation of proton pump inhibitors |
| IT1392813B1 (it) * | 2009-02-06 | 2012-03-23 | Dipharma Francis Srl | Forme cristalline di dexlansoprazolo |
| WO2011004387A2 (en) | 2009-06-18 | 2011-01-13 | Matrix Laboratories Ltd | Process for the preparation of dexlansoprazole polymorphic forms |
| IT1395118B1 (it) | 2009-07-29 | 2012-09-05 | Dipharma Francis Srl | Procedimento per la preparazione di dexlansoprazolo cristallino |
| WO2011020189A1 (en) * | 2009-08-19 | 2011-02-24 | Apotex Pharmachem Inc. | Forms of dexlansoprazole and processes for the preparation thereof |
| WO2011098938A1 (en) * | 2010-02-11 | 2011-08-18 | Orchid Chemicals And Pharmaceuticals Limited | Novel solvate of dexlansoprazole |
| WO2011139414A2 (en) * | 2010-04-27 | 2011-11-10 | Dr. Reddy's Laboratories Ltd. | Dexlansoprazole polymorphic forms |
| US20140357870A1 (en) * | 2011-06-21 | 2014-12-04 | Ranbaxy Laboratories Limited | Process for the preparation of dexlansoprazole |
| CN102234265B (zh) * | 2011-08-08 | 2013-11-20 | 天津市汉康医药生物技术有限公司 | 兰索拉唑化合物 |
| WO2013140120A1 (en) | 2012-03-22 | 2013-09-26 | Cipla Limited | Glycerol solvate forms of (r) - 2 - [ [ [3 -methyl -4 (2,2, 2 - trifluoroethoxy) pyridin- 2 - yl] methyl] sulphinyl] - 1h - ben zimidazole |
| CN104177333A (zh) * | 2013-05-24 | 2014-12-03 | 四川海思科制药有限公司 | 一种理化性质稳定的(r)-2-[[[3-甲基-4-(2,2,2-三氟乙氧基)-2-吡啶基]甲基]亚磺酰基]-1h-苯并咪唑 |
| CN104650035A (zh) * | 2013-11-25 | 2015-05-27 | 天津市汉康医药生物技术有限公司 | 右兰索拉唑倍半水合物化合物 |
| WO2016174664A1 (en) | 2015-04-29 | 2016-11-03 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
| IT201700050223A1 (it) * | 2017-05-09 | 2018-11-09 | Dipharma Francis Srl | Procedimento per la preparazione di dexlansoprazolo cristallino |
| PL3495422T3 (pl) | 2017-12-05 | 2021-05-31 | Borealis Ag | Kompozycja polipropylenowa wzmocniona włóknami |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6150978A (ja) | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | ピリジン誘導体およびその製造法 |
| TW385306B (en) * | 1996-11-14 | 2000-03-21 | Takeda Chemical Industries Ltd | Method for producing crystals of benzimidazole derivatives |
| JP3283252B2 (ja) | 1999-06-17 | 2002-05-20 | 武田薬品工業株式会社 | ベンズイミダゾール化合物の結晶 |
| TWI289557B (en) * | 1999-06-17 | 2007-11-11 | Takeda Chemical Industries Ltd | A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole |
| JP3374314B2 (ja) | 2000-05-15 | 2003-02-04 | 武田薬品工業株式会社 | 結晶の製造法 |
| CN100562318C (zh) * | 2000-05-15 | 2009-11-25 | 武田药品工业株式会社 | 晶体的制备方法 |
| JP4160293B2 (ja) | 2000-12-01 | 2008-10-01 | 武田薬品工業株式会社 | 結晶の製造法 |
| US6627646B2 (en) * | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
| AU2003273000A1 (en) * | 2002-10-16 | 2004-05-04 | Takeda Pharmaceutical Company Limited | Stable solid preparations |
| MY148805A (en) | 2002-10-16 | 2013-05-31 | Takeda Pharmaceutical | Controlled release preparation |
| ITMI20062481A1 (it) * | 2006-12-22 | 2008-06-23 | Recordati Chem Pharm | Processo per la preparazione di lansoprazolo forma i microcristallino |
-
2008
- 2008-12-30 JP JP2010541519A patent/JP2011507977A/ja not_active Abandoned
- 2008-12-30 US US12/811,190 patent/US20100286400A1/en not_active Abandoned
- 2008-12-30 CA CA2738458A patent/CA2738458A1/en not_active Abandoned
- 2008-12-30 EP EP10183275A patent/EP2292612A3/en not_active Withdrawn
- 2008-12-30 CA CA002676477A patent/CA2676477A1/en not_active Withdrawn
- 2008-12-30 EP EP08870108A patent/EP2227462A1/en not_active Withdrawn
- 2008-12-30 WO PCT/US2008/088534 patent/WO2009088857A1/en not_active Ceased
- 2008-12-30 EP EP12192439A patent/EP2573082A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011507977A5 (enExample) | ||
| MY150833A (en) | Crystal of benzimidazole compound | |
| HRP20151299T1 (hr) | Kristalni (r)-(e)-2-(4-(2-(5-(1-(3,5-diklorpiridin-4-il)etoksi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol i njegova upotreba kao inhibitora fgfr | |
| EP2292612A3 (en) | Crystalline solvated forms of (r)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1h-benzimidazole | |
| RU2009122242A (ru) | Кристаллические формы сольватированного илапразола | |
| JP2015501799A5 (enExample) | ||
| JP2012512885A5 (enExample) | ||
| RU2009136593A (ru) | Кристаллические формы 6-[2-(метилкарбамоил)фенилсульфанил]-3-е-[2-(пиридин-2-ил)этенил]индазола, пригодные для лечения аномального роста клеток у илекопитаюших | |
| JP2013507408A5 (enExample) | ||
| JP2012505884A5 (enExample) | ||
| JP2010535814A5 (enExample) | ||
| JP2009536652A5 (enExample) | ||
| NO20084915L (no) | Nikotinacetylcholinreseptorligander 101 | |
| JP2009506014A5 (enExample) | ||
| GEP20186839B (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
| JP2015500331A5 (enExample) | ||
| WO2008006795A3 (en) | Indole compounds | |
| JP2013538857A5 (enExample) | ||
| JP2020536893A5 (enExample) | ||
| JP2011519873A5 (enExample) | ||
| JP2009532434A5 (enExample) | ||
| IL195796A (en) | Crystalline Compound (r) –5– [2– (6,5– Diethyl – Yadan – 2 – Ylamino) –1 – Hydroxyethyl] –8 – Hydroxy –1 H– Quinoline-2 – On Acetate, Dry Powder Pharmaceuticals And its use in the preparation of medicines to treat asthma or obstructive pulmonary disease | |
| JP2011520991A5 (enExample) | ||
| JP2008503574A5 (enExample) | ||
| CA2695973A1 (en) | Novel salt of isoquinoline compound and crystal thereof |